Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Defence Therapeutics Inc (OP: DTCFF )

0.4140 UNCHANGED
Last Price Updated: 11:38 AM EDT, Oct 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.4140
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.4140
Today's Range 0.4140 - 0.4140
52wk Range 0.4000 - 2.180
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors
(November 14, 2023) - Defence Therapeutics Inc. (CSE:DTC) (OTC Pink:DTCFF) (FSE:DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in 
Via PressReach
Exposures Product Safety
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia

Performance

YTD
-74.76%
-74.76%
1 Month
+1.05%
+1.05%
3 Month
-24.65%
-24.65%
6 Month
-60.19%
-60.19%
1 Year
-80.47%
-80.47%

More News

Read More
Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
Via PressReach
Topics Intellectual Property
Exposures Intellectual Property
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
Via FinancialNewsMedia
Defence’s Novel Accutox(TM) Continues to Surprise on Results Against Cancer
Via PressReach
Exposures Product Safety
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
Via PressReach
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
Via PressReach
Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science
Via PressReach
Defence’s Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines
Via PressReach
BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment
Via Newsfile
BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News
Via Newsfile
Topics Supply Chain
Exposures Supply Chain
Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market
Via Newsfile
Topics Death Intellectual Property
Exposures Death Intellectual Property
Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma
Via Newsfile
Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative
Via Newsfile
Defence Therapeutics Scores Again With New Planned Phase 1 Trial Evaluating Its DC Cancer AccuVAC-D002 Against Melanoma; Puts Second Catalyst In Play (OTCMKTS: DTCFF)
Via AB Newswire
Defence Therapeutics ACCUM™ Technology Can Be A Treatment Game-Changer And Beating Breast Cancer Is In Its Crosshairs (OTCMKTS: DTCFF)
Via AB Newswire
Defence Therapeutics Draws Interest As Planned Phase 1 Breast Cancer Drug Trial Nears; Posts 116% Gain Since May (OTCMKTS: DTCFF)
Via AB Newswire
Defence Therapeutics Is Advancing Next-Generation Vaccine Technology To Beat Cancers And Virus, Even After They Mutate (OTCMKTS: DTCFF)
Via AB Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.